<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The global incidence of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is increasing </plain></SENT>
<SENT sid="1" pm="."><plain>Although there are emerging epigenetic factors that contribute to the occurrence, development and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, the biological significance of epigenetic molecular regulation in different subpopulations such as <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cells remains to be elucidated </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we investigated the functional roles of the H3K4 demethylase, jumonji, AT rich interactive domain 1B (JARID1B), an epigenetic factor required for the continuous cell growth of <z:hpo ids='HP_0002861'>melanomas</z:hpo>, in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We found that CD44(+)/<z:chebi fb="1" ids="17478">aldehyde</z:chebi> dehydrogenase (ALDH)(+) slowly proliferating immature <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> stem cell populations expressed relatively low levels of JARID1B and the differentiation marker, CD20, as well as relatively high levels of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor, p16/INK4A </plain></SENT>
<SENT sid="4" pm="."><plain>Of note, lentiviral‑mediated continuous JARID1B <z:mpath ids='MPATH_63'>depletion</z:mpath> resulted in the loss of epithelial differentiation and suppressed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell growth, which was associated with the induction of phosphorylation by the c‑Jun N‑terminal kinase (Jnk/Sapk) and senescence‑associated β‑galactosidase activity </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, green fluorescent‑labeled cell tracking indicated that JARID1B‑positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells had greater tumorigenicity than JARID1B‑negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells after their subcutaneous inoculation into immunodeficient mice, although JARID1B‑negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells resumed <z:mpath ids='MPATH_458'>normal</z:mpath> growth after a month, suggesting that continuous JARID1B inhibition is necessary for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> eradication </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, JARID1B plays a role in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> maintenance </plain></SENT>
<SENT sid="7" pm="."><plain>JARID1B may be a novel molecular target for therapy‑resistant <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells by the induction of cellular senescence </plain></SENT>
</text></document>